NEW SENATE LABOR & HUMAN RESOURCES COMMITTEE MEMBERS
Executive Summary
NEW SENATE LABOR & HUMAN RESOURCES COMMITTEE MEMBERS include Senators-elect Mikulski (D-Md.) and Adams (D-Wash.), according to tentative committee assignments made Nov. 21 by the Senate Democratic Conference. They will join new Chairman Kennedy (D-Mass.) on the committee. Barbara Mikulski, 50, is a five-term representative from Baltimore with a background in social work and a liberal voting record. A veteran of the House Energy & Commerce Committee, Mikulski has been a strong supporter of government regulatory policies and programs to aid the needy. She was elected to the Senate seat of Charles Mathias (R), who retired. Kennedy knows Mikulski well: at his request she would have delivered his nominating speech at the 1980 national convention had he won the Democratic presidential nomination. Brock Adams, 59, was Transportation Department secretary during the Carter Administration after serving as a congressman for 12 years. He defeated Republican Sen. Slade Gorton. Another new face on the the Kennedy committee will be Sen. Harkin (D-Iowa). He is entering the third year of his freshman term in the Senate, where he previously served on the Agriculture, Appropriations, and Small Business Committees. Harkin is considered an articulate and aggressive liberal who has voted for government relief programs.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth